| Sign In to gain access to subscriptions and/or personal tools. |
IL-1RA in refractory systemic lupus erythematosusSecond Medical Department, University Hospital Schleswig Holstein, Kiel, Germany, fmoosig{at}aol.com
Second Medical Department, University Hospital Schleswig Holstein, Kiel, Germany
Second Medical Department, University Hospital Schleswig Holstein, Kiel, Germany
Second Medical Department, University Hospital Schleswig Holstein, Kiel, Germany There is evidence from animal and human studies that IL-1 might play an important role in the development and maintainence of inflammation in systemic lupus erythemathosus (SLE). We hypothesized that, in SLE, there might be a relative deficiency in the physiologic antagonist of IL-1, IL-1 receptor antagonist (IL-1RA). We therefore treated three patients with active SLE in whom conventional therapy has failed with the human IL-1RA, Anakinra. In two of the three patients there was a transient effect on muscle pain and/or polyarthritis. In one patient with lupus myositis there was no effect at all. The therapy was well tolerated and the only significant side effect was a transient drop in complement levels (C3 and C4) without clinical or laboratory signs of increased SLE activity in all three patients.
Key Words: IL1-RA • SLE
Lupus, Vol. 13, No. 8,
605-606 (2004) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
